The Experts below are selected from a list of 156588 Experts worldwide ranked by ideXlab platform
James J. Ferguson - One of the best experts on this subject based on the ideXlab platform.
-
relation between procedural activated Coagulation time and outcome after percutaneous transluminal coronary angioplasty
Journal of the American College of Cardiology, 1994Co-Authors: James J. Ferguson, Kathryn G Dougherty, Carlos M Gaos, Kathryn Marsh, Howard S Bush, Richard D LeachmanAbstract:Objectives. The purpose of this study was to determine whether a low procedural activated Coagulation time is associated with a high rate of in-hospital complications and to identify whether there is an activated Coagulation time range that may be associated with a low rate of complications. Background. In recent years the activated Coagulation time has come into widespread use for monitoring antiCoagulation in the catheterization laboratory. However, considerable controversy exists as to the standards by which to judge “adequate” antiCoagulation for interventional procedures. Methods. From a total of 1,469 consecutive patients with percutaneous transluminal coronary angioplasty, we retrospectively identified 103 (Group I, 7% of the overall population) with major complications of death or emergency or urgent coronary artery bypass graft surgery and compared them with 400 patients without complications (Group II). Group I patients had more high risk clinical characteristics, such as type B and C lesions, class III and IV angina, recent myocardial infarction and recent thrombolytic treatment. Activated Coagulation times were compared between Groups I and II at baseline, after administration of 10,000 U of heparin and at the end of the procedure. Results. There were no differences in baseline activated Coagulation times between Groups I and II. Group I had significantly lower activated Coagulation times after heparin therapy and at the end of the procedure: 61% 300 s; 279 of Group II had activated Coagulation times 27% 300 s (p 300 s. Conclusions. A diminished activated Coagulation time response to an initial bolus of heparin is associated with major in-hospital complications after coronary angioplasty, although patients with complications did have a higher risk before the procedure. It remains to be determined whether there is an ideal “target” activated Coagulation time for interventional procedures.
-
comparison of hemochron and hemotec activated Coagulation time target values during percutaneous transluminal coronary angioplasty
Journal of the American College of Cardiology, 1994Co-Authors: Amilcar Avendano, James J. FergusonAbstract:Objectives. The aim of this study was to determine whether activated Coagulation time measurements from Hemochrem and HemoTec machines can be used interchangeably and whether similar activated Coagulation time target ranges for adequate antiCoagulation can be applied to both machines. Background. Adequate antiCoagulation is necessary for the safe performance of intravascular interventions such as percutaneous transluminal coronary angioplasty. In current practice, antiCoagulation status is frequently assessed by way of the activated Coagulation time one of two commercially available systems, HemoTec and Hemochron. Each one employs a different technique to determine the time of clot formation; however, the same terget activated Coagulation time values for adequate antiCoagulation have been used interchangeably in published studies. Methods. A total of 311 paired samples were compared in 113 high risk patients undergoing angioplasty enrolled in a randomized trial of a platelet glycoprotein IIb/IIIa receptor antibody. Simultaneous activated Coagulation time measurements were obtained before and after administration of heparin, and the difference between the values of both machines was calculated. The relation between the Hemochron and HemoTec values was determined by using linear regression analysis. All activated Coagulation time measurements were classified as either therapeutic or subtherapeutic using an arbitrary activated Coagulation time target of 300 s. Results. There was a correlation between values from the two machines (r = 0.86), but the Hemochron values were consistently higher than the HemoTec values by a mean value ± SD of 28 ± 29%, with wide individual variation. After heparin administration, there was a signaificant (p < 0.0001) difference between the number of measurements classified as therapeutic by HemoTec (53%) and by Hemochron (94%). Conclusions. HemoTec and Hemochron activated Coagulation time measurements cannot be used interchangeably. Appropriate target activated Coagulation time ranges to determine adequate antiCoagulation during coronary angioplasty need to be established for both machines; the target range for one machine should not be extrapolated to the other.
Richard D Leachman - One of the best experts on this subject based on the ideXlab platform.
-
relation between procedural activated Coagulation time and outcome after percutaneous transluminal coronary angioplasty
Journal of the American College of Cardiology, 1994Co-Authors: James J. Ferguson, Kathryn G Dougherty, Carlos M Gaos, Kathryn Marsh, Howard S Bush, Richard D LeachmanAbstract:Objectives. The purpose of this study was to determine whether a low procedural activated Coagulation time is associated with a high rate of in-hospital complications and to identify whether there is an activated Coagulation time range that may be associated with a low rate of complications. Background. In recent years the activated Coagulation time has come into widespread use for monitoring antiCoagulation in the catheterization laboratory. However, considerable controversy exists as to the standards by which to judge “adequate” antiCoagulation for interventional procedures. Methods. From a total of 1,469 consecutive patients with percutaneous transluminal coronary angioplasty, we retrospectively identified 103 (Group I, 7% of the overall population) with major complications of death or emergency or urgent coronary artery bypass graft surgery and compared them with 400 patients without complications (Group II). Group I patients had more high risk clinical characteristics, such as type B and C lesions, class III and IV angina, recent myocardial infarction and recent thrombolytic treatment. Activated Coagulation times were compared between Groups I and II at baseline, after administration of 10,000 U of heparin and at the end of the procedure. Results. There were no differences in baseline activated Coagulation times between Groups I and II. Group I had significantly lower activated Coagulation times after heparin therapy and at the end of the procedure: 61% 300 s; 279 of Group II had activated Coagulation times 27% 300 s (p 300 s. Conclusions. A diminished activated Coagulation time response to an initial bolus of heparin is associated with major in-hospital complications after coronary angioplasty, although patients with complications did have a higher risk before the procedure. It remains to be determined whether there is an ideal “target” activated Coagulation time for interventional procedures.
Amilcar Avendano - One of the best experts on this subject based on the ideXlab platform.
-
comparison of hemochron and hemotec activated Coagulation time target values during percutaneous transluminal coronary angioplasty
Journal of the American College of Cardiology, 1994Co-Authors: Amilcar Avendano, James J. FergusonAbstract:Objectives. The aim of this study was to determine whether activated Coagulation time measurements from Hemochrem and HemoTec machines can be used interchangeably and whether similar activated Coagulation time target ranges for adequate antiCoagulation can be applied to both machines. Background. Adequate antiCoagulation is necessary for the safe performance of intravascular interventions such as percutaneous transluminal coronary angioplasty. In current practice, antiCoagulation status is frequently assessed by way of the activated Coagulation time one of two commercially available systems, HemoTec and Hemochron. Each one employs a different technique to determine the time of clot formation; however, the same terget activated Coagulation time values for adequate antiCoagulation have been used interchangeably in published studies. Methods. A total of 311 paired samples were compared in 113 high risk patients undergoing angioplasty enrolled in a randomized trial of a platelet glycoprotein IIb/IIIa receptor antibody. Simultaneous activated Coagulation time measurements were obtained before and after administration of heparin, and the difference between the values of both machines was calculated. The relation between the Hemochron and HemoTec values was determined by using linear regression analysis. All activated Coagulation time measurements were classified as either therapeutic or subtherapeutic using an arbitrary activated Coagulation time target of 300 s. Results. There was a correlation between values from the two machines (r = 0.86), but the Hemochron values were consistently higher than the HemoTec values by a mean value ± SD of 28 ± 29%, with wide individual variation. After heparin administration, there was a signaificant (p < 0.0001) difference between the number of measurements classified as therapeutic by HemoTec (53%) and by Hemochron (94%). Conclusions. HemoTec and Hemochron activated Coagulation time measurements cannot be used interchangeably. Appropriate target activated Coagulation time ranges to determine adequate antiCoagulation during coronary angioplasty need to be established for both machines; the target range for one machine should not be extrapolated to the other.
D Liberti - One of the best experts on this subject based on the ideXlab platform.
-
Coagulation support algorithm with rapid teg and functional fibrinogen teg in critical bleeding more results and less time
Critical Care, 2015Co-Authors: E De Blasio, C Pellegrini, A Federico, V Rocco, Maurizio Fumi, Ylenia Pancione, Silvia Sale, D LibertiAbstract:Early Coagulation support is essential in massively bleeding patients. A Coagulation Support Algorithm (CSA), integrating rapid TEG (r-TEG) and functional fibrinogen TEG (ff-TEG) could shorten the time to a tailored treatment (Figure (Figure11). Figure 1 Coagulation Support Algorithm. Methods A retrospective comparison of the time to available TEG and Standard Coagulation Tests (SCT: INR, aPTTr, fibrinogen level) results in two groups of bleeding and coagulopathic patients using citrate kaolin-TEG (k-TEG) or the CSA protocol (r-TEG/ff-TEG). Statistical analysis was performed with Student's t test for unpaired samples.
M Akhnak - One of the best experts on this subject based on the ideXlab platform.
-
ultrasonic measurement of milk Coagulation time
Measurement Science and Technology, 2001Co-Authors: F. Bakkali, A. Amghar, Ali Moudden, B Faiz, Montero F De Espinosa, Gérard Maze, M AkhnakAbstract:Using a pulse reflection technique an ultrasonic system has been developed to monitor in situ the Coagulation process of rennetted milk. The velocity and attenuation of ultrasonic waves through coagulating milk were continuously monitored. The observed changes in ultrasonic velocity during Coagulation were used to predict the Coagulation time. The Coagulation time is indicative of the transition from the enzymatic phase to the physicochemical phase. The determination of Coagulation time has a decisive role in determining the qualities of the end product in cheesemaking.
